ABL1 and leukemia: Previous studies have demonstrated that B-ALL leukemia stem cells (B-LSCs) are enriched during GFP+B220+CD43+ population in BCR-ABL induced B-ALL mouse models and they could not be completely eliminated by Dasatinib.24 To test whether high-expression of Tspan32 also impedes B-LSCs, leukemia Pro-B and Pre-B cells were examined.